Gemigliptin tartrate

Modify Date: 2024-01-08 09:38:36

Gemigliptin tartrate Structure
Gemigliptin tartrate structure
Common Name Gemigliptin tartrate
CAS Number 1374639-74-3 Molecular Weight 639.45
Density N/A Boiling Point N/A
Molecular Formula C22H25F8N5O8 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Gemigliptin tartrate


Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications[1][2].

 Names

Name Gemigliptin tartrate

 Gemigliptin tartrate Biological Activity

Description Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications[1][2].
Related Catalog
Target

IC50: 10.3 nM (human recombinant DPP-4)[2]

In Vitro Gemigliptin tartrate dose-dependently inhibits the formation of AGE-BSA with IC50 of 11.69 mM[1]. Gemigliptin tartrate dose-dependently suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM[1]. Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM[2].
In Vivo Gemigliptin tartrate (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo[1]. Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2]. Animal Model: Male C57BL/KsJ-db/db mice (7 weeks old)[1] Dosage: 100 mg/kg Administration: Oral gavage, daily, for 12 weeks Result: Significantly reduced circulating AGE levels by 44.5% in serum.
References

[1]. Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102.

[2]. Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.

 Chemical & Physical Properties

Molecular Formula C22H25F8N5O8
Molecular Weight 639.45